Can MDMA play a role in the treatment of substance abuse?

Current Drug Abuse Reviews

Volumn 6, Issue 1, 2013, Pages 54-62

  Jerome, Lisa ^a   Schuster, Shira ^b   Yazar Klosinski, B Berra ^a  

^a Multidisciplinary Association for Psychedelic Studies   (United States)

^b NEW SCHOOL FOR SOCIAL RESEARCH   (United States)

Author keywords

3,4 methylenedioxymethamphetamine; Addiction; Entactogen; MDMA; Oxytocin; Psychedelic; Psychotherapy

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ANOREXIA; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; BRUXISM; COGNITIVE DEFECT; DISTRESS SYNDROME; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; GAIT DISORDER; HEART RATE; HUMAN; HYPERTHERMIA; HYPONATREMIA; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ANIMALS; BRAIN; COMBINED MODALITY THERAPY; HALLUCINOGENS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PSYCHOTHERAPY; SUBSTANCE-RELATED DISORDERS;

EID: 84880180218     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/18744737112059990005     Document Type: Article

References (126)

1. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Emergency Department Visits Involving Ecstasy. 2011; Rockville, MD.
2. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2011; 9: CD005031.
3. Mayet S, Farrell M, Ferri M, Amato L, Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev 2005; 1: CD004330.
4. Mayet S, Farrell M, Ferri M, Amato L, Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev 2010; 9: CD005031.
5. Clapp P. Current progress in pharmacologic treatment strategies for alcohol dependence. Expert Rev Clin Pharmacol 2012; 5(4): 427-35.
6. Abadinsky H. Drug Use and Abuse: A Comprehensive Introduction. 7th ed. Belmont: Wadsworth 2011.
7. Maisto SA, Galizio M, Connors GJ. Drug Use and Abuse. 7th ed. Belmont: Wadsworth 2011.
8. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. J Clin Psychiatry 2004; 6(4): 159-66.
9. Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev 2010; 1: CD007024.
10. Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2009; 3: CD002025.
11. Schroeder SA. How clinicians can help smokers to quit. JAMA 2012; 308(15): 1586-7.
12. Krebs TS, Johansen PO. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 2012; 26(7): 994-1002.
13. Mangini M. Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoactive Drugs 1998; 30(4): 381-418.
14. Sessa B. Is there a case for MDMA-assisted psychotherapy in the UK? J Psychopharmacol 2007; 21(2): 220-4.
15. Shulgin A, Shulgin A. Pihkal: A Chemical Love Story. 1st ed. Berkeley: Transform Press 1991.
16. Shulgin AT, Nichols DE. Characterization of three new psychotomimetics. In: Stillman RC, Willette RE, Ed. The Pharmacology of Hallucinogens. New York: Pergamon 1978.
17. Freudenmann RW, Oxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction 2006; 101(9): 1241-5.
18. Shulgin A. History of MDMA. In: Peroutka SJ, Ed. Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Boston: Kluwer Academic Publishers 1990.
19. Benzenhofer U, Passie T. Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction 2010; 105(8): 1355-61.
20. Holland J. The history of MDMA. In: Holland J, Ed. Ecstasy, A Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA. Rochester: Inner Traditions 2001. pp. 11-20.
21. Metzner R, Adamson S. Using MDMA in healing, psychotherapy and spiritual practice. In: Holland J, Ed. Ecstasy, A Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA. Rochester: Inner Traditions 2001. pp. 182-207.
22. Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986; 18(4): 319-27.
23. Bouso JC, Doblin R, Farre M, Alcazar MA, Gomez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs 2008; 40(3): 225-36.
24. Mithoefer M, Wagner M, Mithoefer A, et al. Durability of Improvement in PTSD symptoms and absence of harmful effects or drug dependency after MDMA-assisted psychotherapy: A prospective long-term follow-up study. J Psychopharmacol 2013; 27(1): 28-39.
25. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 2011; 25(4): 439-52.
26. Oehen P, Traber, R., Widmer, V., Schnyder, U. Pilot study of MDMA-assisted psychotherapy for treatment-resistant PTSD. J Psychopharmacol 2013; 2013; 27(1): 40-52.
27. Chwelos N, Blewett DB, Smith CM, Hoffer A. Use of d-lysergic acid diethylamide in the treatment of alcoholism. Q J Stud Alcohol 1959; 20: 577-90.
28. Jensen SE. Treatment of chronic alcoholism with lysergic acid diethylamide. Can Psychiatr Assoc J 1963; 8: 182-8.
29. Bogenschutz MP, Pommy JM. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses. Drug Test Anal 2012; 4(7-8): 543-55.
30. Beck J, Rosenbaum M. In Pursuit of Ecstasy: The MDMA Experience. Albany: SUNY Press 1994.
31. Wise RA. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res 2008; 14(2-3): 169-83.
32. Hommer DW, Bjork JM, Gilman JM. Imaging brain response to reward in addictive disorders. Ann N Y Acad Sci 2011 Jan; 1216: 50-61.
33. Wise RA. The role of reward pathways in the development of drug dependence. Pharmacol Ther 1987; 35(1-2):227-63.
34. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988; 85(14): 5274-8.
35. Agboola S, McNeill A, Coleman T, Leonardi Bee J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 2010; 105(8): 1362-80.
36. Bala MM, Lesniak W, Strzeszynski L. Efficacy of pharmacological methods used for treating tobacco dependence: meta-analysis. Pol Arch Med Wewn 2008;118(1-2): 20-8.
37. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179(2): 135-44.
38. Marshall RD, Johannet CM, Collins PY, Smith H, Kahn DA, Douglas CJ. Bupropion and sertraline combination treatment in refractory depression. J Psychopharmacol 1995; 9(3): 284-6.
39. Farre M, Abanades S, Roset PN, et al. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 2007; 323(3): 954-62.
40. Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000; 22(5): 513-21.
41. Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 2001; 16(8): 589-98.
42. Tancer M, Johanson CE. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2007; 189(4): 565-73.
43. Verrico CD, Miller GM, Madras BK. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) 2007; 189(4): 489-503.
44. Hysek CM, Simmler LD, Ineichen M, et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (ecstasy) in humans. Clin Pharmacol Ther 2011; 90(2): 246-55.
45. Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (ecstasy) in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998; 19(4): 241-51.
46. Liechti ME, Geyer MA, Hell D, Vollenweider FX. Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology 2001; 24(3): 240-52.
47. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX. Psychological and physiological effects of MDMA (Ecstasy) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 2000; 23(4): 396-404.
48. van Wel JH, Kuypers KP, Theunissen EL, Bosker WM, Bakker K, Ramaekers JG. Blockade of 5-HT(2) Receptor Selectively Prevents MDMA-Induced Verbal Memory Impairment. Neuropsychopharmacology 2011; 36(9): 1932-9.
49. Bartz JA, Hollander E. The neuroscience of affiliation: forging links between basic and clinical research on neuropeptides and social behavior. Horm Behav 2006; 50(4): 518-28.
50. Wolff K, Tsapakis EM, Winstock AR, et al. Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol 2006; 20(3): 400-10.
51. Dumont GJ, Sweep FC, van der Steen R, et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci 2009; 4(4): 359-66.
52. Hysek CM, Domes G, Liechti ME. MDMA enhances mind reading of positive emotions and impairs mind reading of negative emotions. Psychopharmacology (Berl) 2012; 222(2): 293-302
53. Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (ecstasy). Neuroscience 2007; 146(2): 509-14.
54. Thompson MR, Hunt GE, McGregor IS. Neural correlates of MDMA (Ecstasy)-induced social interaction in rats. Soc Neurosci 2009; 4(1): 60-72.
55. Broadbear JH, Tunstall B, Beringer K. Examining the role of oxytocin in the interoceptive effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') using a drug discrimination paradigm in the rat. Addict Biol 2011; 16(2): 202-14.
56. Hunt GE, McGregor IS, Cornish JL, Callaghan PD. MDMAinduced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635. Brain Res Bull 2011; 86(1-2): 65-73.
57. Olff M, Langeland W, Witteveen A, Denys D. A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. CNS Spectr 2010; 15(8): 522-30.
58. McGregor IS, Bowen MT. Breaking the loop: oxytocin as a potential treatment for drug addiction. Horm Behav 2012; 61(3): 331-9.
59. Carson DS, Cornish JL, Guastella AJ, Hunt GE, McGregor IS. Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamineseeking behaviour in rats. Neuropharmacology 2010; 58(1): 38-43.
60. Carson DS, Hunt GE, Guastella AJ, et al. Systemically administered oxytocin decreases methamphetamine activation of the subthalamic nucleus and accumbens core and stimulates oxytocinergic neurons in the hypothalamus. Addict Biol 2010; 15(4): 448-63.
61. Churchland PS, Winkielman P. Modulating social behavior with oxytocin: how does it work? What does it mean? Horm Behav 2012; 61(3): 392-9.
62. MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 2011; 36(8): 1114-26.
63. Cami J, Farre M, Mas M, et al. Human pharmacology of 3,4-methylenedioxymethamphetamine (ecstasy): psychomotor performance and subjective effects. J Clin Psychopharmacol 2000; 20(4): 455-66.
64. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2002; 162(4): 396-405.
65. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 2001; 154(2): 161-8.
66. Tancer M, Johanson CE. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 2003; 72(1): 33-44.
67. Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 2010; 5(8): e12412.
68. Liester MB, Grob CS, Bravo GL, Walsh RN. Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 1992; 180(6): 345-52; discussion 53-4.
69. Nichols DE, Oberlender R. Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs? Ann N Y Acad Sci 1990; 600: 613-23; discussion 623-5.
70. Bedi G, Hyman D, de Wit H. Is ecstasy an empathogen? Effects of +/-3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry 2010; 68(12): 1134-40.
71. Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX. 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology 2000; 23(4): 388-95.
72. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord 2011; 25(3): 456-65.
73. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Psychiatric comorbidity of full and partial posttraumatic stress disorder among older adults in the United States: results from wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Am J Geriatr Psychiatry 2012; 20(5): 380-90.
74. Bedi G, Phan KL, Angstadt M, de Wit H. Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl) 2009; 207(1):73-83.
75. Fantegrossi WE, Woolverton WL, Kilbourn M, et al. Behavioral and neurochemical consequences of long-term intravenous selfadministration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology 2004; 29(7): 1270-81.
76. Schenk S, Gittings D, Johnstone M, Daniela E. Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology (Berl) 2003; 169(1): 21-7.
77. Trigo JM, Panayi F, Soria G, Maldonado R, Robledo P. A reliable model of intravenous MDMA self-administration in naive mice. Psychopharmacology (Berl) 2006; 184(2):212-20.
78. Lile JA, Ross JT, Nader MA. A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) with cocaine in rhesus monkeys. Drug Alcohol Depend 2005; 78(2): 135-40.
79. Wee S, Woolverton WL. Self-administration of mixtures of fenfluramine and amphetamine by rhesus monkeys. Pharmacol Biochem Behav 2006; 84(2): 337-43.
80. Johanson CE, Kilbey M, Gatchalian K, Tancer M. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among damphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend 2006; 81(1): 27-36.
81. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration 2011 Contract No.: 11-4658
82. von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen HU. Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults-a transient phenomenon? Results from a longitudinal community study. Drug Alcohol Depend 2002; 66(2): 147-59.
83. Cottler LB, Womack SB, Compton WM, Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol 2001; 16(8): 599-606.
84. Lester SJ, Baggott M, Welm S, et al. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebocontrolled trial. Ann Intern Med 2000; 133(12): 969-73.
85. Mas M, Farre M, de la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290(1): 136-45.
86. Kuypers KP, Wingen M, Ramaekers JG. Memory and mood during the night and in the morning after repeated evening doses of MDMA. J Psychopharmacol 2008; 22(8): 895-903.
87. Kuypers KP, Ramaekers JG. Transient memory impairment after acute dose of 75mg 3.4-Methylene-dioxymethamphetamine. J Psychopharmacol 2005; 19(6): 633-9.
88. Kuypers KP, Ramaekers JG. Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected. Psychopharmacology (Berl) 2007; 189(4): 557-63.
89. Kuypers KP, Wingen M, Heinecke A, Formisano E, Ramaekers JG. MDMA intoxication and verbal memory performance: a placebocontrolled pharmaco-MRI study. J Psychopharmacol 2011; 25(8): 1053-61.
90. Hall AP, Henry JA. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 2006; 96(6): 678-85.
91. Liechti ME, Kunz I, Kupferschmidt H. Acute medical problems due to Ecstasy use. Case-series of emergency department visits. Swiss Med Wkly 2005; 135(43-44): 652-7.
92. Rogers G, Elston J, Garside R, et al. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess 2009; 13(6): iii-iv, ix-xii, 1-315.
93. Gouzoulis-Mayfrank E, Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 2006; 101(3): 348-61.
94. Bedi G, Redman J. Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds. Psychol Med 2008; 38(9): 1319-30.
95. Halpern JH, Sherwood AR, Hudson JI, Gruber S, Kozin D, Pope HG, Jr. Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. Addiction 2011; 106(4): 777-86.
96. Roiser JP, Rogers RD, Sahakian BJ. Neuropsychological function in ecstasy users: a study controlling for polydrug use. Psychopharmacology (Berl) 2007; 189(4): 505-16.
97. Hoshi R, Mullins K, Boundy C, Brignell C, Piccini P, Curran HV. Neurocognitive function in current and ex-users of ecstasy in comparison to both matched polydrug-using controls and drugnaive controls. Psychopharmacology (Berl) 2007; 194(3): 371-9.
98. Selvaraj S, Hoshi R, Bhagwagar Z, et al. Brain serotonin transporter binding in former users of MDMA ('ecstasy'). Br J Psychiatry 2009; 194(4): 355-9.
99. Cole JC, Sumnall HR. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 2003; 27(3): 199-217.
100. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Pharmacol Rev 2003; 55(3): 463-508.
101. O'Callaghan JP, Miller DB. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994; 270(2): 741-51.
102. Baumann MH, Wang X, Rothman RB. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 2007; 189(4): 407-24.
103. Mechan A, Yuan J, Hatzidimitriou G, Irvine RJ, McCann UD, Ricaurte GA. Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 2006; 31(2): 339-50.
104. Erritzoe D, Frokjaer VG, Holst KK, et al. In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) and hallucinogen users. Arch Gen Psychiatry 2011; 68(6): 562-76.
105. Kish SJ, Fitzmaurice PS, Chang LJ, Furukawa Y, Tong J. Low striatal serotonin transporter protein in a human polydrug MDMA (ecstasy) user: a case study. J Psychopharmacol 2010; 24(2): 281-4.
106. Bell SE, Burns DT, Dennis AC, Matchett LJ, Speers JS. Composition profiling of seized ecstasy tablets by Raman spectroscopy. Analyst 2000; 125(10): 1811-5.
107. Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA. The content of ecstasy tablets: implications for the study of their longterm effects. Addiction 2002; 97(12): 1531-6.
108. Wood DM, Stribley V, Dargan PI, Davies S, Holt DW, Ramsey J. Variability in the 3,4-methylenedioxymethamphetamine content of 'ecstasy' tablets in the UK. Emerg Med J 2011; 28(9): 764-5.
109. Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink RJ. Content of ecstasy in the Netherlands: 1993-2008. Addiction 2009; 104(12): 2057-66.
110. Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, Zehnder J. Chemical analysis of ecstasy pills. JAMA 2000; 284(17): 2190.
111. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(5): 819-27.
112. Quednow BB, Jessen F, Kuhn KU, Maier W, Daum I, Wagner M. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction. J Psychopharmacol 2006; 20(3): 373-84.
113. Zakzanis KK, Campbell Z. Memory impairment in now abstinent MDMA users and continued users: a longitudinal follow-up. Neurology 2006; 66(5): 740-1.
114. Verbaten MN. Specific memory deficits in ecstasy users? The results of a meta-analysis. Hum Psychopharmacol 2003; 18(4): 281-90.
115. Schilt T, de Win MM, Koeter M, et al. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Arch Gen Psychiatry 2007; 64(6): 728-36.
116. Halpern JH, Pope HG, Jr., Sherwood AR, Barry S, Hudson JI, Yurgelun-Todd D. Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 2004; 75(2): 135-47.
117. McDevitt-Murphy ME, Murphy JG, Monahan CM, Flood AM, Weathers FW. Unique patterns of substance misuse associated with PTSD, depression, and social phobia. J Dual Diagn 2010; 6(2): 94-110.
118. Norman SB, Tate SR, Wilkins KC, Cummins K, Brown SA. Posttraumatic stress disorder's role in integrated substance dependence and depression treatment outcomes. J Subst Abuse Treat 2010; 38(4): 346-55.
119. Mills KL, Teesson M, Ross J, Darke S. The impact of posttraumatic stress disorder on treatment outcomes for heroin dependence. Addiction 2007; 102(3): 447-54.
120. Hien DA, Jiang H, Campbell AN, et al. Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network. Am J Psychiatry 2010; 167(1): 95-101.
121. Ouimette P, Moos RH, Finney JW. PTSD treatment and 5-year remission among patients with substance use and posttraumatic stress disorders. J Consult Clin Psychol 2003; 71(2): 410-4.
122. Brady KT, Killeen TK, Brewerton T, Lucerini S. Comorbidity of psychiatric disorders and posttraumatic stress disorder. J Clin Psychiatry 2000; 61 Suppl 7: 22-32.
123. Brown PJ, Wolfe J. Substance abuse and post-traumatic stress disorder comorbidity. Drug Alcohol Depend 1994; 35(1): 51-9.
124. Olff M, Langeland W, Gersons BP. The psychobiology of PTSD: coping with trauma. Psychoneuroendocrinology 2005; 30(10): 974-82.
125. Hruska B, Fallon W, Spoonster E, Sledjeski EM, Delahanty DL. Alcohol use disorder history moderates the relationship between avoidance coping and posttraumatic stress symptoms. Psychol Addict Behav 2011; 25(3): 405-14.
126. Stolaroff M. The Secret Chief Revealed: Conversations with a pioneer of the underground therapy movement. Sarasota: Multidisciplinary Association for Psychedelic Studies 2004.